Sun, Dec 21, 2014, 1:14 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • howardmorris howardmorris Sep 27, 2012 8:12 PM Flag

    Enspirit for non-small cell lung cancer

    I know you guys all know this and Summer has prob written a treatise about it somewhere...but this board looks LONELY, lol...

    ABOUT ENSPIRIT

    ENSPIRIT is an international, randomized, open-label study that will enroll approximately 1,100 patients with advanced or metastatic NSCLC who have been previously treated with a first-line platinum-based chemotherapy and have documented disease progression. Patients will be randomized to receive custirsen plus docetaxel or docetaxel alone. The primary objective of the study will be overall survival with additional secondary and exploratory analyses of other efficacy outcomes and biomarker relationships. Two formal interim analyses are planned for stopping the trial early based on inadequate evidence of clinical benefit or futility. No interim analyses for claiming efficacy are planned.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Some one posted recently on Medivations FDA approval. I think MDVN offers a interesting road map for OGXI. The MDVN run started in the months before the anouncement of end of patient accural for their PIII trial and resulted in a 20 fold increase in shareholder value over the ensuing 2 years.I do not know where the tipping point is in this stock but I think we are VERY close.

    • Couldn't agree more Howard. Wish I had something to add but I'm just posting to help address the lonely board problem. Now on to waiting for them to announce that SYNERGY has completed enrollment. After which I guess we wait some more.

 
OGXI
2.03-0.2500(-10.96%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.